The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | A CIBMTR study investigating the effect of donor type on transplantation outcomes in myelofibrosis
Tania Jain, MBBS, Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University, Baltimore, MD, discusses the findings of a study using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry data to investigate the effect of donor type on stem cell transplantation (SCT) outcomes in patients with myelofibrosis (MF). This analysis highlighted that the availability of a fully matched donor should not delay SCT in patients who require it, as haploidentical donor transplants confer similar survival to matched unrelated donor (MUD) transplants. Further investigation is needed to develop optimal strategies to prevent graft failure, especially in haploidentical SCT. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Institutional research support from CTI Biopharma, Kartos therapeutics, Incyte, Bristol Myers Squibb, Tscan; Advisory board participation with Bristol Myers Squibb, Incyte, Abbvie, CTI, Kite, Cogent Biosciences, Blueprint Medicine, Telios pharma, Protagonist therapeutics, Galapagos, Tscan therapeutics, Karyopharm, Morphosys, In8Bio.
